Since 2011, several novel first-line unresectable or metastatic malignant melanoma therapies have gained approval in the U.S. and in Europe. These agents, namely immunotherapies and BRAF and MEK inhibitors, have revolutionized the treatment landscape of malignant melanoma, considerably improving patients’ survival. Despite the remarkable improvement in survival, the prevailing unmet needs in first-line unresectable or metastatic malignant melanoma therapies still consolidate around the improvements in efficacy, creating a significant clinical and commercial opportunity for drug developers to exploit with new therapies which can extend patients lives.

Table of contents

  • Detailed, Expanded Analysis: First-Line Unresectable or Metastatic Melanoma
    • Treatment Drivers and Goals
      • Overview
      • Treatment Drivers and Goals
        • Methodology
        • Physician Weighting of Clinical and Non-Clinical Attributes
        • Rationale for Treatment Drivers and Goals Selection
      • Physician Rating of Treatment Drivers and Goals in First-line Unresectable or Metastatic Malignant Melanoma
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
      • Stated Versus Derived Importance of Treatment Drivers and Goals
    • Product Performance Against Treatment Drivers and Goals
      • Overview
      • Rationale for Drug Selection
      • Current Brand Performance on Key Treatment Drivers and Goals
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
    • Assessment of Unmet Need
      • Overview
      • Overall Satisfaction with Current Treatment
      • Physician Rating of Unmet Need in First-line Unresectable or Metastatic Malignant Melanoma
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
      • Unmet Need in First-line Unresectable or Metastatic Malignant Melanoma and Related Indications
    • Opportunity Analysis
      • Areas of Opportunity in the Malignant Melanoma Market and Emerging Therapy Insights
        • Opportunity: A Novel Agent with a Substantial Survival Benefit
        • Opportunity: A New Agent That Elicits Better Responses
        • Opportunity: A New Agent That Elicits More Durable Responses
        • Opportunity: A Novel Therapy with a Lower Incidence of Immune-Related Adverse Events Compared to PD-
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
      • Attribute Importance and Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Scenario 1
        • Scenario 2

Author(s): Michalina Jenkins, MSc, PhD

Michalina Jenkins, , is a business insights analyst in the oncology team at Decision Resources Group. She is a specialist in malignant melanoma and has expertise in prostate cancer. Dr. Jenkins obtained her doctorate in molecular biology of cancer from University of London, where she focused on investigating the impact of phosphoinositide 3-kinases (PI3Ks) signaling on cancer cell biology. Dr. Jenkins holds a in pharmacology from the University of Oxford and a in biotechnology from Oxford Brookes University. Dr. Jenkins worked as a research assistant at Oxford Gene Technology where she was involved in microarray gene expression analysis and R&D projects developing novel gene expression analysis platforms.


Related Reports

Malignant Melanoma | Unmet Need | Detailed, Expanded Analysis: BRAF-Mutation-Positive, Unresectable or Metastatic Malignant Melanoma

Treatment of BRAF-mutation-positive unresectable or metastatic malignant mel...

View Details

Malignant Melanoma | Landscape & Forecast | Disease Landscape & Forecast

Although the malignant melanoma market has become increasingly crowded, an evolving trend of combining drug classes to create novel therapies is expanding treatment options for patients. While bo...

View Details